Mina Sooch - Gemphire Therapeutics President CEO

CEO

Ms. Mina Patel Soochis is President, Chief Executive Officer, Director of the Company. Prior to joining Gemphire Therapeutics, she served from 2012 to 2014 as the CEO of ProNAi, a clinicalstage oncology company, and a board director from its founding in 2004 through 2014. At ProNAi, Ms. Sooch pioneered a new drug modality, DNAi, led the execution of Phase I and II trials on PNT2258 and raised over 70M in Series C and D financing from top tier institutional investors. The last round of 60M was the largest VC financing ever in Michigans history. Prior to her operating role, she has spent over a decade in life sciences VC through founding of Apjohn Ventures and also as EIR at Northcoast Technology Investors. As a VC, she led the sourcing and evaluation of deals across therapeutic areas, the investment terms and syndication, the governance, the followon financings totaling over 300M, and the exits of several life sciences companies. Also, she cofounded three startups . Notable exits from the Apjohn portfolio include the acquisition of ZyStor by BioMarin in 2010, the acquisition of Afmedica by Angiotech Pharmaceuticals in 2005, and the product acquisition from Ikano by UpsherSmith in 2010 since 2014.
Age 48
Tenure 10 years
Professional MarksMBA
Phone734-245-1700
Webhttp://www.gemphire.com
Sooch has served on over 10 private, public, and VC industry boards including ProNAi, ZyStor, Asterand, Cytopherx, Svelte, Wolverine Venture Fund, and Michigan VC Association. Earlier in her career from 19932000, she served as global account manager at Monitor Group, a top tier global strategy consulting firm based in Boston. In 1995, she worked on the multibillion Pharmacia & Upjohn merger. Mina received a MBA from Harvard Business School in 1993. She graduated summa cum laude and commencement speaker from Wayne State University in 1989 with a B.S. in Chemical Engineering.

Gemphire Therapeutics Management Efficiency

The company has return on total asset (ROA) of (44.9) % which means that it has lost $44.9 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (280.97) %, meaning that it created substantial loss on money invested by shareholders. Gemphire Therapeutics' management efficiency ratios could be used to measure how well Gemphire Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

CEO Age

Francisco MackennaCompania Cervecerias Unidas
57
Matias BebinCompania Cervecerias Unidas
N/A
Stephen ArcosCompania Cervecerias Unidas
N/A
Pedro AguadoCompania Cervecerias Unidas
50
Alvaro GarciaCompania Cervecerias Unidas
N/A
Claudio MelendezCompania Cervecerias Unidas
N/A
Francisco DominguezCompania Cervecerias Unidas
59
Marco DallolioCompania Cervecerias Unidas
N/A
Alvaro MarambioCompania Cervecerias Unidas
N/A
Fernando SacchiCompania Cervecerias Unidas
59
Hugo ZalazarCompania Cervecerias Unidas
N/A
Fernando MoraCompania Cervecerias Unidas
N/A
Jose NasrallahCompania Cervecerias Unidas
58
Alvaro RomanCompania Cervecerias Unidas
N/A
Claudio LizanaCompania Cervecerias Unidas
N/A
Matias SubercaseauxCompania Cervecerias Unidas
N/A
Carlos DiazCompania Cervecerias Unidas
N/A
Domingo ManterolaCompania Cervecerias Unidas
39
Francisco BarriocanalCompania Cervecerias Unidas
N/A
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease . The company was founded in 2008 and is headquartered in Livonia, Michigan. Gemphire Therapeutics operates under Biotechnology classification in USA and is traded on Nasdaq Capital Markets. It employs 7 people. Gemphire Therapeutics (GEMP) is traded on NASDAQ Exchange in USA and employs 7 people.

Management Performance

Gemphire Therapeutics Leadership Team

Elected by the shareholders, the Gemphire Therapeutics' board of directors comprises two types of representatives: Gemphire Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gemphire. The board's role is to monitor Gemphire Therapeutics' management team and ensure that shareholders' interests are well served. Gemphire Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gemphire Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Bisgaier, Co-Founder, Chief Scientific Officer
Mina Sooch, President CEO
Kenneth Kousky, Independent Director
Andrew Sassine, Independent Director
Jeffrey Mathiesen, CFO
Seth Reno, Chief Commercial Officer
Pedro Lichtinger, Independent Director
Steven Gullans, Interim President Interim CEO, Director
David Lowenschuss, Co-Founder, Chief Legal Officer
Kent Hawryluk, Independent Director
Lee Golden, Chief Medical Officer

Gemphire Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gemphire Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Gemphire Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Gemphire Therapeutics' short interest history, or implied volatility extrapolated from Gemphire Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Other Consideration for investing in Gemphire Stock

If you are still planning to invest in Gemphire Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gemphire Therapeutics' history and understand the potential risks before investing.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Content Syndication
Quickly integrate customizable finance content to your own investment portal
CEOs Directory
Screen CEOs from public companies around the world
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Money Managers
Screen money managers from public funds and ETFs managed around the world